Our study, which was published in 2022, confirmed that patients with sarcopenia who underwent albumin-paclitaxel chemotherapy experienced a significant increase in the incidence of grade ≥ 3 neurotoxicity and neutropenia (30, 31). This evidence concerns the gene ALB and Decreased total neutrophil count.